Thermo Fisher Scientific Awarded $192.5 Million U.S. Government Contract to Expand Domestic Pipette Tip Manufacturing

- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a $192.5 million contract award from the U.S. Department of Defense (DoD) to ensure reliable domestic production of pipette tips, which are used within research and diagnostic labs to dispense precise amounts of liquid. In mid-2020, the company announced its own investments to increase pipette tip production capacity to support COVID-19 testing.

With the DoD award, issued on behalf of and in coordination with the U.S. Department of Health and Human Services (HHS), Thermo Fisher will co-invest with the U.S. government in building a new, state-of-the-art, energy efficient manufacturing facility for pipette tips, which are used in vital disease research and in high volumes for processing of diagnostic tests nationally, including COVID-19, during the pandemic.

The new center of excellence in laboratory consumables manufacturing and operations will be in North Carolina and designed in line with Thermo Fisher's carbon neutrality goals. Construction will be fully completed by Q3 2024, with pipette tip manufacturing starting as early as Q3 2023. The site, expected to create hundreds of new jobs in the region, has the potential for future expansion across a variety of high-demand product lines.

"This award and the resulting capacity ensure that future demand surges in the U.S., from the current COVID-19 pandemic to the next crisis, will be met with greater supply assurance," said Mark Stevenson , executive vice president and chief operating officer. "Supply chain agility is critical to our customers, our government and to the health and safety of our citizens, and we're excited to bring this state-of-the-art capacity online, especially since its efficient design will also showcase our commitment to achieve net-zero carbon emissions by 2050."

Laboratory consumables have been vital in global COVID-19 mobilization, from sample collection vials for diagnostic test kits to lab plastics and materials for vaccine production and biobanking. Since the start of the pandemic, Thermo Fisher has invested more than $180 million to expand its laboratory plastics consumables production and another $600 million to increase global bioprocessing capacity. In addition, the company opened new sites dedicated to manufacturing viral transport media used in COVID-19 sample collection and cGMP plasmid DNA used in mRNA-based vaccines.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone:  781-622-1356
E-mail: rafael.tejada@thermofisher.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-awarded-192-5-million-us-government-contract-to-expand-domestic-pipette-tip-manufacturing-301367950.html

SOURCE Thermo Fisher Scientific

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.

This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and prevention of diseases and physical conditions, and it continues to develop rapidly.

Examples of medical devices include neurostimulation devices, surgical implants, ultrasound imaging devices and robotic medical technology, along with insulin pumps and insulin pens for diabetes. Just as pharmaceutical companies seek to serve unmet needs, medical device companies do the same via innovative technologies.

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Latest Press Releases

Related News

×